Occurrence of Selected Generic Drugs 3

    Basic Details
    Date Posted
    Thursday, December 13, 2012
    Status
    Complete
    Medical Product
    alosetron HCL
    ambrisentan
    bosentan
    buprenorphine HCL
    fentanyl
    hydromorphone HCL
    isotretinoin
    lenalidomide
    methadone HCL
    morphine sulfate
    naloxone HCL
    oxycodone HCL
    rosiglitazone maleate
    rosiglitazone/glimepiride
    rosiglitazone/metformin HCL
    thalidomide
    Description

    Summary table assessment of the use of Alosetron hydrochloride (HCL), Ambrisentan, Bosentan, Buprenorphine HCL, Buprenorphine HCL/Naloxone HCL, Fentanyl, Hydromorphone HCL, Isotretinoin, Lenalidomide, Methadone HCL, Morphine sulfate, Oxycodone HCL, Rosiglitazone Maleate, Rosiglitazone/Glimepiride, Rosiglitazone/Metformin HCL, and Thalidomide. Results were generated using the Mini-Sentinel Distributed Query Tool and the Dispensing Summary Table.Summary tables are precompiled stratified counts. Queries were executed in September 2011. This report includes data from 15 Data Partners.

    If you are using a web page screen reader and are unable to access this document, please use the Contact Us page for assistance or send an email requesting assistance to info@sentinelsystem.org.

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    2000 - 2010
    Study Type
    Summary Table
    Assessment Type
    Exploratory Analyses
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)